Wright W Nichols Selected Research

Ceftazidime (Fortum)

1/2022	The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
1/2019	Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
4/2018	Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.
1/2018	A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
4/2017	Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
1/2017	Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
1/2016	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
4/2015	Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.
11/2014	Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.
1/2014	Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wright W Nichols Research Topics

Disease

14	Infections 01/2022 - 12/2012
3	Healthcare-Associated Pneumonia 03/2020 - 12/2014
3	Pneumonia (Pneumonitis) 03/2016 - 01/2014
2	Abdominal Abscess 01/2022 - 04/2018
2	Ventilator-Associated Pneumonia 03/2020 - 01/2019
2	Intraabdominal Infections 01/2019 - 12/2015
2	Urinary Tract Infections (Urinary Tract Infection) 01/2019 - 12/2015
1	Critical Illness (Critically Ill) 03/2020
1	Obesity 01/2019
1	Cystic Fibrosis (Mucoviscidosis) 11/2018
1	Abscess 04/2018
1	Body Weight (Weight, Body) 04/2015

Drug/Important Bio-Agent (IBA)

13	ceftazidime drug combination avibactamIBA 01/2022 - 12/2012
11	Ceftazidime (Fortum)FDA LinkGeneric 01/2022 - 12/2012
9	avibactamIBA 01/2022 - 01/2014
9	LactamsIBA 01/2022 - 11/2014
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2014
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 12/2014
2	Meropenem (Merrem)FDA LinkGeneric 03/2020 - 04/2018
1	CreatinineIBA 01/2019
1	CephalosporinaseIBA 11/2018
1	Aztreonam FDA LinkGeneric 04/2017
1	Ceftaroline FDA Link 04/2017
1	Carbapenems (Carbapenem Antibiotics)IBA 12/2015
1	Pulmonary Surfactants (Pulmonary Surfactant)IBA 12/2014

Therapy/Procedure

2	Therapeutics 01/2022 - 11/2014
1	Intravenous Infusions 01/2019